New MR procedure may help save women from unnecessary breast biopsies

NewsGuard 100/100 Score

A new MR procedure that uses diffusion-weighted imaging (DWI) to determine whether or not a breast lesion is malignant or benign may help reduce unnecessary breast biopsies, according to a study performed at the National Institute of Health in Bethesda, MD.

DWI is a method that produces images detecting the exchange of water molecules between tissue compartments (diffusion).

The study included 80 patients with 85 lesions. Quantitative analysis of DWI was used to determine whether or not a lesion was benign or malignant. "Using diffusion-weighted imaging can reflect the cellular density of a lesion without using contrast," said Riham El-Khouli, MD, lead author of the study. "The quantitative analysis of DWI correctly identified that 50 of 60 lesions as malignant. At the same time, it correctly identified that 23 of 25 of the lesions were benign. Lesions with higher cellular density are more likely to be malignant," she said.

"MR imaging of the breast is very common. It is typically used for screening patients with an increased risk of developing breast cancer (patients with a personal or family history of breast or ovarian cancer and patients with certain genetic mutations). It is also used for some patients who have been recently diagnosed with breast cancer or for patients with complex mammograms," said Dr. El-Khouli.

This new MR method that uses diffusion-weighted imaging only adds to the benefits of using MR for breast imaging by improving the ability of MRI to characterize benign from malignant lesions. Hopefully, this procedure will help save women from unnecessary breast biopsies by decreasing the false-positive rates of MRI," said Dr. El-Khouli.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New Lancet Commission on Breast Cancer: Transforming breast cancer care globally